A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer
about
Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in JapanHigh efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.Long-term suppression of lymphangitic lung metastasis from breast cancer using biweekly docetaxel: a case report.Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer.Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.Phase II study of weekly docetaxel in patients with metastatic breast cancer.Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer.Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.Docetaxel: a new active agent in the therapy of metastatic breast cancer.
P2860
Q33329495-2F6EDAD9-7A93-4141-8789-EE66ADDC1B27Q33365694-F1A4B5F0-27D4-472F-868E-1DA5BBD700C5Q33366094-7219552D-689B-4CC7-8026-CB882D719B7FQ35591657-8D811559-9374-4E23-89DF-F3C3AEBB6530Q36646250-6C4CFD40-046B-4B06-94F6-92A6896228D2Q36649028-55268144-AF36-4FE9-8B4B-3C2D51E39BB7Q36996241-68B9E8D5-E564-4CBC-A6D7-9D772417DAFAQ37957744-F53C5DD0-59DC-4B9A-82C6-57DB48E33922Q40192736-79637854-507C-40A9-921F-0CB79D03AD21Q40549902-4DF3E845-574B-47B3-BB86-2FBEDC65E34DQ40588127-0F3B1760-A4F5-471D-8812-8594135E0335Q43910370-1FB2BC96-D01B-4F01-B546-CFA99EC89E75Q44726905-FBAE158C-B654-405F-B3DE-0A34EE4B46FBQ45190962-672F8B5C-F76B-4C44-83B3-6A996F399A0DQ46078166-04B82ACD-B409-41B9-966B-D575C2B98FA3Q46421756-71BB3C43-4ADC-4C6E-8FA7-C9BD38E9548CQ53853229-422024A3-E9F5-473F-8090-4664CBD02680
P2860
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
A multicentre phase II study o ...... search and Treatment of Cancer
@ast
A multicentre phase II study o ...... search and Treatment of Cancer
@en
type
label
A multicentre phase II study o ...... search and Treatment of Cancer
@ast
A multicentre phase II study o ...... search and Treatment of Cancer
@en
prefLabel
A multicentre phase II study o ...... search and Treatment of Cancer
@ast
A multicentre phase II study o ...... search and Treatment of Cancer
@en
P2093
P2860
P356
P1476
A multicentre phase II study o ...... search and Treatment of Cancer
@en
P2093
B Chevallier
I Krakowski
J L Misset
M Murawsky
P Fumoleau
P2860
P2888
P304
P356
10.1038/BJC.1996.416
P407
P577
1996-08-01T00:00:00Z